The impact of whole-brain radiation therapy on the long-term control and morbidity of patients surviving more than one year after gamma knife radiosurgery for brain metastases

Varlotto, John M.; Flickinger, John C.; Niranjan, Ajay; Bhatnagar, Ajay; Kondziolka, Douglas; Lunsford, L. Dade

doi:10.1016/j.ijrobp.2004.12.092

Cited by 65 publications

(41 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus some dose escalation is likely needed for this pathological subtype. The experience with radiosugery for metastastic brain tumors suggests that even lower doses chosen by previous investigators have high efficacy [20]. Based on all the studies taken together, it is fair to say that homogeneity of dose to the target tissue is not a priority.…”

Section: Dose and Fractionationmentioning

confidence: 99%

Stereotactic Body Radiation Therapy (SBRT) for lung metastases

et al. 2006

View full text Add to dashboard Cite

Section: Dose and Fractionationmentioning

confidence: 99%

Stereotactic Body Radiation Therapy (SBRT) for lung metastases

et al. 2006

View full text Add to dashboard Cite

“…Результаты СРХ как самостоятельного метода лечения значительно варьируют в зависимости от исследования: 1-летний уровень локального контроля составляет 70-95 % [27][28][29], в то время как 2-5-летний уровень снижается до 50-70 %. В проспективном рандомизированном исследовании [30] при однофракционной СРХ 1-лет-ний локальный контроль составил 72,5 %, а 2-летний снизился до 48 %.…”

Section: '2015unclassified

“…Разница в опухолевом контроле зависит от гисто-логической принадлежности опухоли, размера и дозы облучения [28]. Лучшие показатели наблюдаются при опухолях менее 2 см в диаметре с краевой СРХ выше 16 Гр.…”

Section: '2015unclassified

“…Ретроспективное исследование из Университета Питтсбурга [28] показало, что сочетание ТОГМ и СРХ улучшило локальный контроль только у пациентов с опухолями > 2 см в диаметре, если доза СРХ  16 Гр. В проспективном исследовании [30], в котором паци-ентов с 1-4 метастазами рандомизировали между СРХ…”

Section: лечение 1-3 метастазовunclassified

See 1 more Smart Citation

The History of Stereotactic Radiosurgery Development and Its Role in the Treatment of Brain Metastases

Энгел¹,

Nazarenko²

2015

Opuholi golovy šei

View full text Add to dashboard Cite

Обзор литературыИстория развития стереотаксической радиохирургии и ее роль в лечении метастазов в головной мозг О. Т. Энгел, А. В. НазаренкоКлиника лучевой хирургии «Онкостоп»; Россия, 115478, Москва, Каширское шоссе, 23, стр. [2,3]. Достижения современной онкологии приводят к увеличению выживаемости больных раком, однако у выживших пациентов с течением времени увеличи-вается риск развития церебральных метастазов [4].Метастазы солидных опухолей составляют 90-95 % от общего количества метастазов в головной мозг, включая поражение мозговых оболочек [5].

show abstract

“…There is no difference in the clinical outcome whether radiotherapy or neurosurgery is used as an intervention. SRS is mainly advocated in situations with one to three metastases [6,27,38,41], while some studies allow up to five lesions [3,49]. Commonly, a single lesion is treated by a surgical approach.…”

Section: Metastasesmentioning

confidence: 99%

Stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT) for neurooncological and neurological diseases: state of the art and future perspectives

Münter

Welker

Jensen

et al. 2013

Innovative Neurosurgery

View full text Add to dashboard Cite

Stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (SRT) are well established in a high number of neurooncological and neurological lesions. Modern technologies discussed in this review, especially the integration of multimodality imaging in the daily clinical routine, will further improve the results of SRS and SRT. Currently, the different technical methods used are comparable regarding the clinical results in different clinical indications. The technological advances allow high treatment flexibility, and therefore, new treatment indications can be established based on the new technologies. In the future, it has to be defined more clearly whether a single fraction, hypofractionated concepts, or fractionated stereotactic radiotherapy is more effective regarding the clinical results and side effects of the therapy. The main area of development for radiosurgery will be stereotactic body radiosurgery. More randomized clinical studies for all possible indications are needed in the next few decades in order to establish radiosurgery more precisely, and also to determine its true value, especially in normal-fractionated radiotherapy. In technological development, the next step has been completed and proton or particle based stereotactic radiosurgery may have increased use in the future.

show abstract

The impact of whole-brain radiation therapy on the long-term control and morbidity of patients surviving more than one year after gamma knife radiosurgery for brain metastases

Cited by 65 publications

References 24 publications

Stereotactic Body Radiation Therapy (SBRT) for lung metastases

Stereotactic Body Radiation Therapy (SBRT) for lung metastases

The History of Stereotactic Radiosurgery Development and Its Role in the Treatment of Brain Metastases

Stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT) for neurooncological and neurological diseases: state of the art and future perspectives

Contact Info

Product

Resources

About